• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.

作者信息

Wan Chao-Ling, Liu Yu-Qing, Liu Fang-Tong, Huang Yuan-Hong, Cao Han-Yu, Huang Si-Man, Tan Kai-Wen, Ge Shuai-Shuai, Wang Miao, Liu Mei-Jing, Wang Zi-Hao, Li Zheng, Xue Sheng-Li, Dai Hai-Ping

机构信息

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

出版信息

Blood Cancer J. 2024 Aug 23;14(1):144. doi: 10.1038/s41408-024-01130-7.

DOI:10.1038/s41408-024-01130-7
PMID:39179571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11344036/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b7c/11344036/1785887fc2d8/41408_2024_1130_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b7c/11344036/1785887fc2d8/41408_2024_1130_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b7c/11344036/1785887fc2d8/41408_2024_1130_Fig1_HTML.jpg

相似文献

1
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.维奈托克联合低甲基化药物与强化化疗治疗新诊断的伴有骨髓发育异常相关改变的急性髓系白血病：基于国际共识分类的倾向评分匹配分析
Blood Cancer J. 2024 Aug 23;14(1):144. doi: 10.1038/s41408-024-01130-7.
2
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.高危骨髓增生异常综合征和急性髓系白血病患者用维奈克拉治疗的真实土耳其经验。
Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):e686-e692. doi: 10.1016/j.clml.2021.04.004. Epub 2021 Apr 20.
3
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.IDH1或IDH2突变的新诊断急性髓系白血病中，去甲基化药物与维奈托克联合治疗对比强化诱导化疗——一项多中心队列研究
Am J Hematol. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. Epub 2024 May 15.
4
Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.维奈托克联合低甲基化药物与阿糖胞苷、阿克拉霉素和粒细胞集落刺激因子化疗作为初治急性髓系白血病的一线治疗：一项倾向评分匹配分析。
Cancer. 2024 Jul 15;130(14):2472-2481. doi: 10.1002/cncr.35278. Epub 2024 Mar 12.
5
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
6
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Venetoclax 联合克拉屈滨、伊达比星和阿糖胞苷强化化疗治疗初诊急性髓系白血病或高危骨髓增生异常综合征患者：来自单中心、单臂、2 期临床试验的一个队列研究。
Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7.
7
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.维奈托克联合地西他滨与强化化疗治疗急性髓系白血病的疗效比较：基于治疗相关死亡率风险的倾向评分匹配分析。
Am J Hematol. 2021 Mar 1;96(3):282-291. doi: 10.1002/ajh.26061. Epub 2020 Dec 24.
8
Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.地西他滨和地西他滨/维奈克拉治疗的急性髓系白血病和骨髓增生异常综合征患者的分子反应
Haematologica. 2024 Aug 1;109(8):2653-2659. doi: 10.3324/haematol.2022.281396.
9
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.克拉屈滨加阿糖胞苷加维奈克拉治疗对维奈克拉加去甲基化药物难治或复发的急性髓系白血病
Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.
10
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.先前接受过低甲基化剂治疗的继发性 AML 患者的一线治疗方法对其结局的影响。
J Hematol Oncol. 2022 Jan 29;15(1):12. doi: 10.1186/s13045-022-01229-z.

引用本文的文献

1
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies.关于使用维奈托克联合靶向和/或免疫疗法对急性髓系白血病进行无化疗管理的综合观点。
Cell Death Discov. 2025 Aug 13;11(1):379. doi: 10.1038/s41420-025-02678-4.
2
Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.维奈托克联合去甲基化药物用于急性髓系白血病诱导治疗的疗效及预后分析：一项关于适应证特异性分层、分子标志物和血液学毒性的多中心真实世界研究
Cancer Cell Int. 2025 Jul 1;25(1):241. doi: 10.1186/s12935-025-03858-z.
3

本文引用的文献

1
A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.伴有 MDS 相关改变的 AML 的真实世界临床结局分析：ICC 与 WHO-HAEM5 标准的比较。
Blood Adv. 2024 Apr 9;8(7):1760-1771. doi: 10.1182/bloodadvances.2023011869.
2
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.维奈托克与低甲基化剂联合治疗初诊急性髓系白血病：301 例连续患者的反应和生存的基因型特征。
Am J Hematol. 2024 Feb;99(2):193-202. doi: 10.1002/ajh.27138. Epub 2023 Dec 10.
3
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.对于接受异基因移植治疗伴有可测量残留病的急性髓系白血病患者，氟达拉滨美法仑减低剂量预处理与基于放疗的清髓性预处理的对比研究
Bone Marrow Transplant. 2025 Feb;60(2):165-174. doi: 10.1038/s41409-024-02491-0. Epub 2024 Dec 18.
4
Emerging roles of cohesin-STAG2 in cancer.黏连蛋白-STAG2在癌症中的新作用。
Oncogene. 2025 Feb;44(5):277-287. doi: 10.1038/s41388-024-03221-y. Epub 2024 Nov 29.
Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML.
新诊断为 AML 的老年和年轻患者中存在骨髓增生异常相关突变提示预后不良。
Blood Cancer J. 2023 Jan 4;13(1):4. doi: 10.1038/s41408-022-00774-7.
4
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.急性髓细胞白血病：2023 年诊断、风险分层和治疗更新。
Am J Hematol. 2023 Mar;98(3):502-526. doi: 10.1002/ajh.26822. Epub 2023 Jan 13.
5
Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.基因特征可预测复发或难治性急性髓系白血病对维奈克拉联合去甲基化药物的反应。
J Intern Med. 2023 Mar;293(3):329-339. doi: 10.1111/joim.13581. Epub 2022 Nov 3.
6
Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia.综合基因组和转录组分析揭示成人混合表型急性白血病中的不同分子亚型。
Am J Hematol. 2023 Jan;98(1):66-78. doi: 10.1002/ajh.26758. Epub 2022 Oct 31.
7
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
8
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
9
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.CPX-351 与 venetoclax 和阿扎胞苷在急性髓系白血病中的真实世界疗效。
Blood Adv. 2022 Jul 12;6(13):3997-4005. doi: 10.1182/bloodadvances.2022007265.
10
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.维奈托克与去甲基化药物在伴原始细胞增多的骨髓增生异常综合征中的真实世界经验。
Am J Hematol. 2022 Jun 1;97(6):E214-E216. doi: 10.1002/ajh.26539. Epub 2022 Mar 24.